Hemispherian
Dr. Wolfram Eichner has over 20 years of experience in the Pharma/Life Science industries working for Beiersdorf AG as well as Fresenius Kabi where he held various executive positions. He has a broad experience in leading and overseeing drug development programs with partners in the US, Canada, and Europe. Since moving to the financial sector, Wolfram can now look back on over 15 years of experience working as Analyst and Fund Advisor for Healthcare-related investments. Currently, he is a founding partner and Managing Director at Apus Capital GmbH, an investment fund with focus on revaluation cases in various industry segments, primarily IT and Pharma/Biotech. Wolfram also served as a Member of the Board of Directors of the French MedTech company Theraclion. He holds an MBA from the Mittelhessen University of Applied Sciences and is a Certified European Financial Analyst (CEFA).
This person is not in the org chart
This person is not in any offices
Hemispherian
Hemispherian is a biotechnology company developing new treatments for the most aggressive types of cancer. Its mission is to development a new drug to treat Glioblastoma Multiforme.